Relationship between polydipsia and antipsychotics: A systematic review of clinical studies and case reports.


Journal

Progress in neuro-psychopharmacology & biological psychiatry
ISSN: 1878-4216
Titre abrégé: Prog Neuropsychopharmacol Biol Psychiatry
Pays: England
ID NLM: 8211617

Informations de publication

Date de publication:
10 01 2020
Historique:
received: 08 07 2019
revised: 24 08 2019
accepted: 27 08 2019
pubmed: 1 9 2019
medline: 5 1 2021
entrez: 1 9 2019
Statut: ppublish

Résumé

This systematic review aimed to elucidate the relationship between polydipsia and antipsychotics. We systematically searched MEDLINE, Embase, and PsycINFO, and included clinical studies and case reports on polydipsia induced or improved by antipsychotics. We identified 61 articles: 1 double-blind randomized controlled trial (RCT), 4 single-arm trials, 1 cross-sectional study, 3 case series, and 52 case reports. The double-blind RCT demonstrated no significant difference in improvement in polydipsia between olanzapine and haloperidol. Two single-arm trials showed that polydipsia improved during clozapine treatment, whereas the other 2 showed that risperidone did not improve polydipsia. The cross-sectional study showed the prevalence of hyponatremia with first-generation antipsychotics (FGAs: 26.1%) and second-generation antipsychotics (SGAs: 4.9%). Two case series reported that clozapine improved polydipsia; the other one indicated that patients with polydipsia who were treated with FGAs had schizophrenia (70.4%) and mental retardation (25.9%). Of 90 cases in the case reports, 67 (75.3%) were diagnosed with schizophrenia. Of 83 cases in which antipsychotic treatment started before the onset of polydipsia, 75 (90.3%) received FGAs, particularly haloperidol (n = 24, 28.9%), and 11 (13.3%) received risperidone. Among 40 cases in which polydipsia was improved following antipsychotic treatment, 36 (90.0%) received SGAs, primarily clozapine (n = 14, 35.0%). Although the causal relationship between polydipsia and antipsychotics remains unclear because of the paucity of high-quality studies, antipsychotics with high affinity to dopamine D

Identifiants

pubmed: 31472167
pii: S0278-5846(19)30573-1
doi: 10.1016/j.pnpbp.2019.109756
pii:
doi:

Substances chimiques

Antipsychotic Agents 0
Receptors, Dopamine D2 0
Clozapine J60AR2IKIC

Types de publication

Case Reports Journal Article Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

109756

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

So Kirino (S)

Yamanashi Prefectural Kita Hospital, Yamanashi, Japan; Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.

Mutsuki Sakuma (M)

Yamanashi Prefectural Kita Hospital, Yamanashi, Japan; Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.

Fuminari Misawa (F)

Yamanashi Prefectural Kita Hospital, Yamanashi, Japan.

Yasuo Fujii (Y)

Yamanashi Prefectural Kita Hospital, Yamanashi, Japan.

Hiroyuki Uchida (H)

Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.

Masaru Mimura (M)

Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.

Hiroyoshi Takeuchi (H)

Yamanashi Prefectural Kita Hospital, Yamanashi, Japan; Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan. Electronic address: hirotak@dk9.so-net.ne.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH